Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis

Huang, Chengying; Lin, Xiaojun; He, Jinmei; Liu, Nan

doi:10.1016/j.ygyno.2021.02.024

Cited by 17 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, we found that the HR and CI value used in the prior meta-analysis (HR 0.63, 95% CI 0.60-0.65) was much different from the actual Kaplan–Meier curves ( Figure 2 D in 27 ). Thus, the Engauge Digitizer software was applied to obtain data from the Kaplan–Meier survival curves according to a method previously described, 32 , 33 , 38 , 39 and the value of HR and CI (HR 0.82, 95% CI 0.51-1.32) was different from that reported by Haisworth et al 27 Moreover, we included another retrospective study by Hasegawa et al. 30 that assessed the effect of site-specific treatment on CUP.…”

Section: Discussionmentioning

confidence: 99%

Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis

Ding

Jiang

et al. 2022

ESMO Open

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis

Ding

Jiang

et al. 2022

ESMO Open

View full text Add to dashboard Cite

“…Studies must report the incidence of ischemic stroke and/or spontaneous intracerebral hemorrhage (ICH) during the first year after cancer diagnosis. If a graphical representation of the data was provided without a corresponding numerical value, the incidence at 1 year was extracted using the Engauge Digitizer software ( 4 , 5 ). As the primary objective of this systematic review was to synthesize the natural history (i.e., incidence) of stroke in the cancer population, our search was limited to only observational studies and we excluded any interventional studies, as they represent a different population—it is estimated that <5% of adult cancer patients enroll in clinical trials ( 6 ), and this population is comparatively much healthier and younger than the general cancer population ( 7 ).…”

Section: Methodsmentioning

confidence: 99%

Incidence of stroke in the first year after diagnosis of cancer—A systematic review and meta-analysis

Lun

Deka

et al. 2022

Front. Neurol.

View full text Add to dashboard Cite

BackgroundPatients newly diagnosed with cancer represent a population at highest risk for stroke. The objective of this systematic review and meta-analysis was to estimate the incidence of stroke in the first year following a new diagnosis of cancer.MethodsWe searched MEDLINE and EMBASE from January 1980 to June 2021 for observational studies that enrolled adults with a new diagnosis of all cancers excluding non-melanoma skin cancer, and that reported the incidence of stroke at 1 year. PRISMA guidelines for meta-analyses were followed. Two reviewers independently extracted data and appraised risk of bias. We used the Dersimonian and Laird random effects method to pool cumulative incidences after logit transformation, and reported pooled proportions as percentages. Statistical heterogeneity was assessed using the I2 statistic.ResultsA total of 12,083 studies were screened; 41 studies were included for analysis. Data from 2,552,121 subjects with cancer were analyzed. The cumulative incidence of total stroke at 1 year was 1.4% (95% CI 0.9–2.2%), while the pooled incidence of ischemic stroke was 1.3% (95% CI 1.0–1.8%) and 0.3% (95% CI 0.1–0.9%) for spontaneous intracerebral hemorrhage (ICH), with consistently high statistical heterogeneity (>99% I2).ConclusionThe estimated incidence of stroke during the first year after a new diagnosis of cancer is 1.4%, with a higher risk for ischemic stroke than ICH. Cancer patients should be educated on the risk of stroke at the time of diagnosis. Future studies should evaluate optimal primary prevention strategies in this high-risk group of patients.Systematic review registrationhttps://osf.io/ucwy9/.

show abstract

“…Similarly, Judson et al analyzed pre-operative blood samples from 64 EOC patients and reported no significant difference in the OS ( p = 0.96) or PFS ( p = 0.72) between patients with and without detectable CTCs at a mean follow-up of 18.7 months [ 196 ]. Given this controversy, Huang et al subsequently conducted a meta-analysis including 1285 patients from 2 clinical trials and 13 retrospective studies that demonstrated a significant association between the presence of CTCs before treatment with surgery or chemotherapy and both OS (HR = 1.79, 95% CI:1.43–2.24, p < 0.00001) and PFS (HR = 1.59, 95%CI:1.30–1.94, p < 0.00001) [ 197 ]. Other studies have suggested that the number of CTCs may be a potential prognostic factor for EOC patients, but the results are limited by small sample sizes and contradictory findings [ 21 , 181 – 183 , 198 – 201 ].…”

Section: Clinical Applications Of Liquid Biopsy For Ovarian Cancermentioning

confidence: 99%

Potential clinical utility of liquid biopsies in ovarian cancer

2022

View full text Add to dashboard Cite

Background Ovarian cancer (OC) is the most lethal gynecologic malignancy worldwide. One of the main challenges in the management of OC is the late clinical presentation of disease that results in poor survival. Conventional tissue biopsy methods and serological biomarkers such as CA-125 have limited clinical applications. Liquid biopsy is a novel sampling method that analyzes distinctive tumour components released into the peripheral circulation, including circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), cell-free RNA (cfRNA), tumour-educated platelets (TEPs) and exosomes. Increasing evidence suggests that liquid biopsy could enhance the clinical management of OC by improving early diagnosis, predicting prognosis, detecting recurrence, and monitoring response to treatment. Capturing the unique tumour genetic landscape can also guide treatment decisions and the selection of appropriate targeted therapies. Key advantages of liquid biopsy include its non-invasive nature and feasibility, which allow for serial sampling and longitudinal monitoring of dynamic tumour changes over time. In this review, we outline the evidence for the clinical utility of each liquid biopsy component and review the advantages and current limitations of applying liquid biopsy in managing ovarian cancer. We also highlight future directions considering the current challenges and explore areas where more studies are warranted to elucidate its emerging clinical potential.

show abstract

Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis

Cited by 17 publications

References 42 publications

Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis

Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis

Incidence of stroke in the first year after diagnosis of cancer—A systematic review and meta-analysis

Potential clinical utility of liquid biopsies in ovarian cancer

Contact Info

Product

Resources

About